Security
Vericel Corporation Common Stock · VCEL
VCELNASDAQCommon stockCurrentCIK 887359Updated Oct 6, 2026
Name history
AASTROM BIOSCIENCES INC · through Nov 14, 2014
VCEL price & chart
Loading TradingView…
NASDAQ:VCEL on TradingView ↗About the company
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.
In the news
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 ↗
Recent filings
4 filing
SCHEDULE 13G/A - filed by Soleus Capital Master Fund, L.P. regarding Vericel Corp
144 filing
4 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 453,274,000Source | 390,405,000Source | 502,866,000Source | 435,608,000Source | 376,839,000Source | 485,627,000Source | 424,587,000Source | 356,661,000Source | 487,969,000Source | 432,722,000Source | 353,657,000Source | 273,003,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 100,403,000Source | 53,681,000Source | 125,358,000Source | 80,532,000Source | 50,291,000Source | 109,295,000Source | 73,490,000Source | 62,938,000Source | 100,092,000Source | 74,520,000Source | 69,088,000Source | 51,067,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 60,426,000Source | 48,479,000Source | 75,712,000Source | 64,290,000Source | 47,996,000Source | 72,383,000Source | 52,899,000Source | 49,934,000Source | 84,634,000Source | 61,375,000Source | 58,356,000Source | 46,539,000Source |
| Inventory, NetUSD | 18,155,000Source | 15,756,000Source | 18,382,000Source | 16,831,000Source | 14,887,000Source | 18,351,000Source | 17,106,000Source | 13,557,000Source | 17,560,000Source | 17,373,000Source | 13,087,000Source | 15,986,000Source |
| Assets, CurrentUSD | 221,967,000Source | 190,520,000Source | 264,730,000Source | 204,577,000Source | 197,386,000Source | 244,064,000Source | 197,640,000Source | 189,718,000Source | 247,437,000Source | 212,777,000Source | 205,631,000Source | 186,866,000Source |
| Operating Lease, Right-of-Use AssetUSD | 66,087,000Source | 71,561,000Source | 62,014,000Source | 67,398,000Source | 73,020,000Source | 63,409,000Source | 68,716,000Source | 73,682,000Source | 64,774,000Source | 70,098,000Source | 73,462,000Source | 41,535,000Source |
| Other Assets, NoncurrentUSD | 395,000Source | 610,000Source | 233,000Source | 447,000Source | 664,000Source | 288,000Source | 501,000Source | 717,000Source | 341,000Source | 556,000Source | 771,000Source | 1,303,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 131,416,000Source | 132,933,000Source | 132,825,000Source | 128,799,000Source | 133,862,000Source | 129,396,000Source | 129,100,000Source | 122,765,000Source | 133,329,000Source | 140,755,000Source | 127,705,000Source | 80,731,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 721,140,000Source | 669,735,000Source | 750,799,000Source | 711,240,000Source | 654,971,000Source | 738,998,000Source | 699,412,000Source | 641,180,000Source | 730,662,000Source | 684,778,000Source | 629,229,000Source | 593,245,000Source |
| Retained Earnings (Accumulated Deficit)USD | -399,540,000Source | -412,622,000Source | -380,393,000Source | -404,614,000Source | -411,721,000Source | -382,599,000Source | -404,061,000Source | -407,039,000Source | -376,297,000Source | -392,815,000Source | -403,177,000Source | -399,995,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 258,000Source | 359,000Source | -365,000Source | 183,000Source | -273,000Source | -168,000Source | 136,000Source | -245,000Source | 275,000Source | 4,000Source | -100,000Source | -978,000Source |
| Stockholders' Equity Attributable to ParentUSD | 321,858,000Source | 257,472,000Source | 370,041,000Source | 306,809,000Source | 242,977,000Source | 356,231,000Source | 295,487,000Source | 233,896,000Source | 354,640,000Source | 291,967,000Source | 225,952,000Source | 192,272,000Source |
| Liabilities and EquityUSD | 453,274,000Source | 390,405,000Source | 502,866,000Source | 435,608,000Source | 376,839,000Source | 485,627,000Source | 424,587,000Source | 356,661,000Source | 487,969,000Source | 432,722,000Source | 353,657,000Source | 273,003,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 45,582,000Source | 41,346,000Source | 52,532,000Source | 41,132,000Source | 43,863,000Source | 47,155,000Source | 39,448,000Source | 36,470,000Source | 49,149,000Source | 50,286,000Source | 45,749,000Source | 37,463,000Source |
| Operating Lease, Liability, CurrentUSD | 13,845,000Source | 6,119,000Source | 14,158,000Source | 13,753,000Source | 5,791,000Source | 14,063,000Source | 11,163,000Source | 6,012,000Source | 13,969,000Source | 9,257,000Source | 6,187,000Source | 4,302,000Source |
| Accounts Payable, CurrentUSD | 15,335,000Source | 20,884,000Source | 20,614,000Source | 12,857,000Source | 25,216,000Source | 19,009,000Source | 16,751,000Source | 19,432,000Source | 15,828,000Source | 23,848,000Source | 22,347,000Source | 16,930,000Source |
| Operating Lease, Liability, NoncurrentUSD | 84,161,000Source | 91,344,000Source | 78,379,000Source | 86,011,000Source | 89,801,000Source | 80,362,000Source | 87,804,000Source | 86,141,000Source | 82,284,000Source | 89,593,000Source | 81,856,000Source | 43,268,000Source |
| Other Liabilities, NoncurrentUSD | 1,673,000Source | 243,000Source | 1,914,000Source | 1,656,000Source | 198,000Source | 1,879,000Source | 1,848,000Source | 154,000Source | 1,896,000Source | 876,000Source | 100,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 16,286,000Source | 14,343,000Source | 17,644,000Source | 14,404,000Source | 12,856,000Source | 13,967,000Source | 11,418,000Source | 11,026,000Source | 19,236,000Source | 17,065,000Source | 17,215,000Source | 16,190,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Short-term InvestmentsUSD | 34,977,000Source | 48,053,000Source | 37,100,000Source | 36,349,000Source | 52,217,000Source | 36,045,000Source | 39,412,000Source | 47,710,000Source | 37,407,000Source | 41,693,000Source | 40,469,000Source | 68,471,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 3,267,000Source | 2,686,000Source | 11,544,000Source | 5,504,000Source | 4,632,000Source | 3,981,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 11,294,000Source | 11,505,000Source | 38,767,000Source | 36,495,000Source | 32,325,000Source | 37,183,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 964,000Source | -267,000Source | 1,230,000Source | 4,286,000Source | -2,899,000Source | 2,605,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,590,000Source | -551,000Source | 2,974,000Source | -287,000Source | 3,049,000Source | 1,437,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 16,383,000Source | 6,600,000Source | 51,910,000Source | 58,163,000Source | 35,311,000Source | 17,687,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -4,201,000Source | -15,142,000Source | -43,937,000Source | -79,034,000Source | -3,130,000Source | -36,206,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,257,000Source | 14,212,000Source | 27,162,000Source | 63,974,000Source | 20,013,000Source | 7,596,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 4,521,000Source | 6,207,000Source | 6,817,000Source | 5,462,000Source | 2,341,000Source | 1,492,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -2,979,000Source | 3,198,000Source | 7,070,000Source | 19,054,000Source | 3,618,000Source | 1,045,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | -21,000Source | -4,000Source | -47,000Source | 0Source | -41,000Source | -39,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 9,203,000Source | -5,344,000Source | 15,043,000Source | -1,817,000Source | 35,799,000Source | -17,474,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 100,403,000Source | 70,350,000Source | 125,358,000Source | 80,532,000Source | 109,295,000Source | 79,705,000Source | 100,092,000Source | 85,049,000Source | 86,866,000Source | 51,067,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 489,000Source | 399,000Source | 383,000Source | 109,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 580,000Source | 628,000Source | 1,166,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 54,000Source | 54,000Source | 215,000Source | 215,000Source | 215,000Source | 90,000Source |
| DepreciationUSD | — | — | 2,800,000Source | 1,200,000Source | 3,500,000Source | 2,700,000Source | 3,100,000Source | 2,500,000Source | 10,900,000Source | 4,900,000Source | 4,000,000Source | — |
| General and Administrative ExpenseUSD | — | — | 18,617,000Source | 16,244,000Source | — | 19,615,000Source | 22,680,000Source | 19,001,000Source | 76,790,000Source | 60,649,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 859,000Source | 148,000Source | 814,000Source | 721,000Source |
| InterestExpenseNonoperatingUSD | — | — | 158,000Source | 154,000Source | 160,000Source | 157,000Source | 160,000Source | 153,000Source | 630,000Source | 614,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 173,000Source | 0Source | 1,043,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 1,808,000Source | 1,578,000Source | 1,954,000Source | 1,657,000Source | 1,851,000Source | 1,657,000Source | 7,007,000Source | 6,410,000Source | 4,632,000Source | 1,341,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 5,074,000Source | -901,000Source | 2,206,000Source | -553,000Source | -6,302,000Source | -11,246,000Source | 16,518,000Source | 10,362,000Source | -3,182,000Source | -16,709,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,624,000Source | 1,564,000Source | 1,772,000Source | 1,476,000Source | 1,762,000Source | 1,546,000Source | 6,333,000Source | 5,991,000Source | 4,096,000Source | 1,070,000Source |
| Operating ExpensesUSD | — | — | 46,135,000Source | 44,118,000Source | 55,968,000Source | 48,642,000Source | 57,330,000Source | 49,065,000Source | 194,555,000Source | 167,588,000Source | 142,040,000Source | 126,846,000Source |
| Operating Lease, ExpenseUSD | — | — | 3,000,000Source | 3,200,000Source | 3,000,000Source | 6,000,000Source | 3,000,000Source | 3,000,000Source | 11,900,000Source | 12,700,000Source | 10,300,000Source | 6,900,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -26,000Source | 140,000Source | -22,000Source | -24,000Source | 71,000Source | 42,000Source | -44,000Source | 195,000Source | 64,000Source | 95,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 1,563,000Source | 9,409,000Source | 13,934,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 24,516,000Source | 6,000,000Source | 3,652,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 67,503,000Source | 57,905,000Source | 77,457,000Source | 63,240,000Source | 68,425,000Source | 52,598,000Source | 276,259,000Source | 237,224,000Source | 197,516,000Source | 163,698,000Source |
| Cost of RevenueUSD | — | — | 17,918,000Source | 16,252,000Source | 21,055,000Source | 16,627,000Source | 19,159,000Source | 16,325,000Source | 70,660,000Source | 65,117,000Source | 61,940,000Source | 54,577,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 39,817,000Source | 38,025,000Source | 48,475,000Source | 41,911,000Source | 49,226,000Source | 41,804,000Source | 166,992,000Source | 142,791,000Source | 120,998,000Source | 106,903,000Source |
| Operating Income (Loss)USD | — | — | 3,450,000Source | -2,465,000Source | 434,000Source | -2,029,000Source | -8,064,000Source | -12,792,000Source | 11,044,000Source | 4,519,000Source | -6,464,000Source | -17,058,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -26,000Source | 140,000Source | -22,000Source | -24,000Source | 71,000Source | 42,000Source | -44,000Source | 195,000Source | 64,000Source | 95,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -901,000Source | — | — | — | — | 17,377,000Source | 10,510,000Source | -2,368,000Source | -15,988,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 859,000Source | 148,000Source | 814,000Source | 721,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 5,074,000Source | -901,000Source | 2,206,000Source | -553,000Source | -6,302,000Source | -11,246,000Source | 16,518,000Source | 10,362,000Source | -3,182,000Source | -16,709,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.1Source | -0.02Source | 0.04Source | -0.01Source | -0.12Source | -0.23Source | 0.33Source | 0.21Source | -0.07Source | -0.35Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.1Source | -0.02Source | 0.04Source | -0.01Source | -0.12Source | -0.23Source | 0.32Source | 0.2Source | -0.07Source | -0.35Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 50,489,000Source | 49,085,000Source | 51,075,000Source | 50,368,000Source | 50,773,000Source | 49,905,000Source | 50,340,000Source | 48,848,000Source | 47,590,000Source | 47,130,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 51,908,000Source | 49,085,000Source | 52,312,000Source | 50,368,000Source | 50,773,000Source | 49,905,000Source | 52,151,000Source | 51,679,000Source | 47,590,000Source | 47,130,000Source |
| Interest Expense (non-operating)USD | — | — | 158,000Source | 154,000Source | 160,000Source | 157,000Source | 160,000Source | 153,000Source | 630,000Source | 614,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 18,617,000Source | 16,244,000Source | — | 19,615,000Source | 22,680,000Source | 19,001,000Source | 76,790,000Source | 60,649,000Source | — | — |
| Gross ProfitUSD | — | — | 49,585,000Source | 41,653,000Source | 56,402,000Source | 46,613,000Source | 49,266,000Source | 36,273,000Source | 205,599,000Source | 172,107,000Source | 135,576,000Source | 109,788,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 17,471,000Source | 10,580,000Source | -2,381,000Source | -15,912,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 600,000Source | 366,000Source |
| Investment Income, InterestUSD | — | — | 1,808,000Source | 1,578,000Source | 1,954,000Source | 1,657,000Source | 1,851,000Source | 1,657,000Source | 7,007,000Source | 6,410,000Source | 4,632,000Source | 1,341,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,624,000Source | 1,564,000Source | 1,772,000Source | 1,476,000Source | 1,762,000Source | 1,546,000Source | 6,333,000Source | 5,991,000Source | 4,096,000Source | 1,070,000Source |
| Operating ExpensesUSD | — | — | 46,135,000Source | 44,118,000Source | 55,968,000Source | 48,642,000Source | 57,330,000Source | 49,065,000Source | 194,555,000Source | 167,588,000Source | 142,040,000Source | 126,846,000Source |
| Operating Lease, ExpenseUSD | — | — | 3,000,000Source | 3,200,000Source | 3,000,000Source | 6,000,000Source | 3,000,000Source | 3,000,000Source | 11,900,000Source | 12,700,000Source | 10,300,000Source | 6,900,000Source |
| Research and Development ExpenseUSD | — | — | 6,318,000Source | 6,093,000Source | 7,493,000Source | 6,731,000Source | 8,104,000Source | 7,261,000Source | 27,563,000Source | 24,797,000Source | 21,042,000Source | 19,943,000Source |
| Revenue Not from Contract with Customer, OtherUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 667,000Source |
| Selling and Marketing ExpenseUSD | — | — | 21,200,000Source | 21,781,000Source | — | 22,296,000Source | 26,546,000Source | 22,803,000Source | 90,202,000Source | 82,142,000Source | — | — |
Filing attachments
ef20062769_ex99-1.htm · 8-K · 2026-01-13
Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary 2025 Financial Results and Business Updates Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., January 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and sev…
Read attachment ↗ef20041599_ex99-1.htm · 8-K · 2025-01-14
EX-99.1 2 ef20041599_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Revenue of $68.2 to $68.7 Million Highest Qu…
Read attachment ↗ef20041599_ex99-2.htm · 8-K · 2025-01-14
EX-99.2 3 ef20041599_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Advanced Therapies for the Sports Medicine & Severe Burn Care Markets 43Rd Annual J.P. Morgan Healthcare Conference January 15, 2025 Forward-Looking Statements 2 Vericel cautions you that all statements other than statements of historical fact included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we …
Read attachment ↗